Oral everolimus inhibits neointimal proliferation in prosthetic pulmonary valved stents in pigs.
Standard
Oral everolimus inhibits neointimal proliferation in prosthetic pulmonary valved stents in pigs. / Kuehne, Titus; Pietzner, Klaus; Lehmkuhl, Hans B; Gelernter, Dinah; Peters, Björn; Krueger, Julia J; Meinus, Carolin; Klimes, Katrin; Brinkert, Florian; Ewert, Peter; Berger, Felix.
In: J HEART VALVE DIS, Vol. 17, No. 4, 4, 2008, p. 465-472.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Oral everolimus inhibits neointimal proliferation in prosthetic pulmonary valved stents in pigs.
AU - Kuehne, Titus
AU - Pietzner, Klaus
AU - Lehmkuhl, Hans B
AU - Gelernter, Dinah
AU - Peters, Björn
AU - Krueger, Julia J
AU - Meinus, Carolin
AU - Klimes, Katrin
AU - Brinkert, Florian
AU - Ewert, Peter
AU - Berger, Felix
PY - 2008
Y1 - 2008
N2 - BACKGROUND AND AIM OF THE STUDY: Growth factor-dependent cell proliferation can cause in-stent neointimal hyperplasia. The study aim was to evaluate whether oral everolimus inhibits the intimal proliferation associated with the implantation of prosthetic pulmonary valved stents. METHODS: Prosthetic pulmonary valves were implanted in 12 pigs (mean bodyweight 25 kg) using a transcatheter technique. Tricuspid valves were prepared from a titanium-coated polymer and sewn into a self-expanding nitinol stent (diameter 20 mm). Valved stents were implanted in the pulmonary position, where they remained for three months. In six animals, treatment with 2 mg/kg everolimus (Certican; Novartis) per day was started three days before implantation and continued throughout the course of the experiment. The other six pigs acted as controls. Adjuvant anticoagulation treatment consisted of acetylsalicylic acid and oral clopidogrel. After three months, hemodynamic valve function was investigated at catheterization and with MRI. At postmortem investigation the valved stents were explanted and subjected to macroscopic, histological and electron microscopic examination. RESULTS: There were no adverse side effects due to everolimus treatment. The overall mean everolimus plasma level during the study was 4.2 +/- 2.4 ng/ml. MRI revealed intact valve function with a regurgitation fraction of 7.3 +/- 4.2% in controls and 4.3 +/- 3.1% in the everolimus group (p
AB - BACKGROUND AND AIM OF THE STUDY: Growth factor-dependent cell proliferation can cause in-stent neointimal hyperplasia. The study aim was to evaluate whether oral everolimus inhibits the intimal proliferation associated with the implantation of prosthetic pulmonary valved stents. METHODS: Prosthetic pulmonary valves were implanted in 12 pigs (mean bodyweight 25 kg) using a transcatheter technique. Tricuspid valves were prepared from a titanium-coated polymer and sewn into a self-expanding nitinol stent (diameter 20 mm). Valved stents were implanted in the pulmonary position, where they remained for three months. In six animals, treatment with 2 mg/kg everolimus (Certican; Novartis) per day was started three days before implantation and continued throughout the course of the experiment. The other six pigs acted as controls. Adjuvant anticoagulation treatment consisted of acetylsalicylic acid and oral clopidogrel. After three months, hemodynamic valve function was investigated at catheterization and with MRI. At postmortem investigation the valved stents were explanted and subjected to macroscopic, histological and electron microscopic examination. RESULTS: There were no adverse side effects due to everolimus treatment. The overall mean everolimus plasma level during the study was 4.2 +/- 2.4 ng/ml. MRI revealed intact valve function with a regurgitation fraction of 7.3 +/- 4.2% in controls and 4.3 +/- 3.1% in the everolimus group (p
M3 - SCORING: Zeitschriftenaufsatz
VL - 17
SP - 465
EP - 472
IS - 4
M1 - 4
ER -
